Yuan, Xianglin
University of Verona · Azienda Ospedaliera Universitaria Integrata Verona
2 papers on CoChatORCID 0000-0003-4653-5388
Most cited papers
- Verified
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 746
- Verified
M2 Macrophage-Derived Exosomes Promote Cell Migration and Invasion in Colon Cancer
Lan, J., Sun, L., Xu, F., Liu, L., Hu, F., Song, D., Hou, Z., Wu, W., Luo, X., Wang, J., et al. (2019) · Cancer Research
Extracellular vesicles in diseaseImmune cells in cancer
Cited by 643
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free